New drug duo tested in fight against tough pancreatic cancer
NCT ID NCT06773130
First seen Nov 17, 2025 · Last updated Apr 15, 2026 · Updated 19 times
Summary
This early-stage study is testing the safety and effectiveness of a new drug combination (HRS-4642 plus nimotuzumab) for people with advanced pancreatic cancer that has returned or spread. The study will enroll about 20 patients to find the right dose and see if the treatment can shrink tumors. It is for adults whose cancer has progressed despite other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.